HS-20094
RISE-1
Regeneron · Phase 3 · Not yet recruiting · Enrollment 3000
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Olatorepatide-Dose 1 | Obesity, no T2D | n/r | n/r | n/r | n/r |
| Olatorepatide-Dose 2 | Obesity, no T2D | n/r | n/r | n/r | n/r |
| Olatorepatide-Dose 3 | Obesity, no T2D | n/r | n/r | n/r | n/r |
| Placebo-Dose 1 | Obesity, no T2D | n/r | n/r | n/r | n/r |
| Placebo-Dose 2 | Obesity, no T2D | n/r | n/r | n/r | n/r |